Stay updated on Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3; no study content or page functionality were altered.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe study record shows new update timestamps in January and February 2026. Older update entries from 2025 were removed, indicating refreshed page information.SummaryDifference0.1%

- Check34 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2; no visible changes to study data, eligibility criteria, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check42 days agoChange DetectedRevision metadata updated from v3.4.0 to v3.4.1; no visible changes to page content or functionality, and to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedThe page now shows a glossary and a 'Last Update Submitted that Met QC Criteria' field, and the FEAR Act label reads 'No FEAR Act Data' with a new revision 3.4.0. The previous capitalization and wording—'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'—along with revision 3.3.4 are removed.SummaryDifference0.1%

- Check57 days agoChange DetectedAdded a 'Last Update Posted' label and removed the 'Last Update Posted (Estimated)' label. This change affects only timestamp display and does not modify study data or page functionality.SummaryDifference0.0%

Stay in the know with updates to Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.